FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170352208> ?p ?o ?g. }

• W2170352208 endingPage "936" @default.
• W2170352208 startingPage "930" @default.
• W2170352208 abstract "Purpose The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC. Patients and Methods Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete response (CR). The primary end point was the clinical benefit rate (CBR), which was defined as CR, partial response, or stable disease (≥ 16 weeks) by RECIST 1.0 criteria. Translational studies were performed to correlate biomarkers with response. Results Thirty-eight patients were enrolled (median age, 62 years; range, 24 to 82 years). Thirty-five patients were evaluable for response. The CBR was 40% (14 of 35 patients); the median number of cycles among responders was 15 (range, seven to 29 cycles). The confirmed objective response rate (RR) was 32% (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29 cycles). Twenty percent of patients (seven of 35 patients) were taken off treatment after a prolonged CR and at the discretion of the treating clinician. None of the patients discontinued treatment as a result of toxicity. Serous histology was the best predictor of lack of response. Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole. Conclusion Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way." @default.
• W2170352208 created "2016-06-24" @default.
• W2170352208 creator A5001744690 @default.
• W2170352208 creator A5009234043 @default.
• W2170352208 creator A5019407817 @default.
• W2170352208 creator A5043064148 @default.
• W2170352208 creator A5045683633 @default.
• W2170352208 creator A5049589636 @default.
• W2170352208 creator A5064318427 @default.
• W2170352208 creator A5068592498 @default.
• W2170352208 creator A5077072219 @default.
• W2170352208 creator A5077427323 @default.
• W2170352208 creator A5078590034 @default.
• W2170352208 creator A5078692182 @default.
• W2170352208 creator A5088751155 @default.
• W2170352208 date "2015-03-10" @default.
• W2170352208 modified "2023-10-14" @default.
• W2170352208 title "Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma" @default.
• W2170352208 cites W1892496998 @default.
• W2170352208 cites W1966226982 @default.
• W2170352208 cites W1967137553 @default.
• W2170352208 cites W1971085650 @default.
• W2170352208 cites W1975352300 @default.
• W2170352208 cites W1978250626 @default.
• W2170352208 cites W1986896421 @default.
• W2170352208 cites W1992523140 @default.
• W2170352208 cites W2018436777 @default.
• W2170352208 cites W2030251608 @default.
• W2170352208 cites W2038246476 @default.
• W2170352208 cites W2044869180 @default.
• W2170352208 cites W2044952888 @default.
• W2170352208 cites W2054371201 @default.
• W2170352208 cites W2076576155 @default.
• W2170352208 cites W2080196131 @default.
• W2170352208 cites W2086078595 @default.
• W2170352208 cites W2096036261 @default.
• W2170352208 cites W2101217308 @default.
• W2170352208 cites W2109529536 @default.
• W2170352208 cites W2113408823 @default.
• W2170352208 cites W2116914991 @default.
• W2170352208 cites W2134947714 @default.
• W2170352208 cites W2139248078 @default.
• W2170352208 cites W2143493034 @default.
• W2170352208 cites W2146511561 @default.
• W2170352208 cites W2150509444 @default.
• W2170352208 cites W2154516141 @default.
• W2170352208 cites W2167188058 @default.
• W2170352208 cites W2167264978 @default.
• W2170352208 cites W2788623587 @default.
• W2170352208 cites W4293241248 @default.
• W2170352208 cites W2412822797 @default.
• W2170352208 doi "https://doi.org/10.1200/jco.2014.58.3401" @default.
• W2170352208 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4348638" @default.
• W2170352208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28023752" @default.
• W2170352208 hasPublicationYear "2015" @default.
• W2170352208 type Work @default.
• W2170352208 sameAs 2170352208 @default.
• W2170352208 citedByCount "225" @default.
• W2170352208 countsByYear W21703522082012 @default.
• W2170352208 countsByYear W21703522082013 @default.
• W2170352208 countsByYear W21703522082014 @default.
• W2170352208 countsByYear W21703522082015 @default.
• W2170352208 countsByYear W21703522082016 @default.
• W2170352208 countsByYear W21703522082017 @default.
• W2170352208 countsByYear W21703522082018 @default.
• W2170352208 countsByYear W21703522082019 @default.
• W2170352208 countsByYear W21703522082020 @default.
• W2170352208 countsByYear W21703522082021 @default.
• W2170352208 countsByYear W21703522082022 @default.
• W2170352208 countsByYear W21703522082023 @default.
• W2170352208 crossrefType "journal-article" @default.
• W2170352208 hasAuthorship W2170352208A5001744690 @default.
• W2170352208 hasAuthorship W2170352208A5009234043 @default.
• W2170352208 hasAuthorship W2170352208A5019407817 @default.
• W2170352208 hasAuthorship W2170352208A5043064148 @default.
• W2170352208 hasAuthorship W2170352208A5045683633 @default.
• W2170352208 hasAuthorship W2170352208A5049589636 @default.
• W2170352208 hasAuthorship W2170352208A5064318427 @default.
• W2170352208 hasAuthorship W2170352208A5068592498 @default.
• W2170352208 hasAuthorship W2170352208A5077072219 @default.
• W2170352208 hasAuthorship W2170352208A5077427323 @default.
• W2170352208 hasAuthorship W2170352208A5078590034 @default.
• W2170352208 hasAuthorship W2170352208A5078692182 @default.
• W2170352208 hasAuthorship W2170352208A5088751155 @default.
• W2170352208 hasBestOaLocation W21703522082 @default.
• W2170352208 hasConcept C121608353 @default.
• W2170352208 hasConcept C126322002 @default.
• W2170352208 hasConcept C126894567 @default.
• W2170352208 hasConcept C141071460 @default.
• W2170352208 hasConcept C143998085 @default.
• W2170352208 hasConcept C203092338 @default.
• W2170352208 hasConcept C2776694085 @default.
• W2170352208 hasConcept C2777176818 @default.
• W2170352208 hasConcept C2778812593 @default.
• W2170352208 hasConcept C2778822529 @default.
• W2170352208 hasConcept C2779699572 @default.
• W2170352208 hasConcept C2779984678 @default.
• W2170352208 hasConcept C31760486 @default.

• next